ALLR
Allarity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
+4.31%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.15
From 52W high−32.02%
Volume184828.00
Market cap$19.25M
P/E (TTM)—
P/S (TTM)55.8x
Div yield—
Key dataSep 18, 2026
Open
$1.15
From 52W high
−32.02%
Volume
184828.00
Market cap
$19.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
38.2
MomentumView details →
1D Return
+4.31%
YTD Return
+9.26%
SummaryUpdated Jun 1, 2026
Allarity Therapeutics, Inc. (NASDAQ:ALLR) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Cambridge, Massachusetts. The company went public in December 2021 and focuses on developing oncology therapeutics using proprietary drug response predictor technology to create companion diagnostics. Allarity operates in the highly specialized field of precision oncology, where treatments are tailored to individual patients based on their likelihood to respond to specific cancer drugs.
Similar companies
Latest newsMore news →
The Japan Patent Office granted Allarity Therapeutics a patent covering its stenoparib-specific Drug Response Predictor companion diagnostic.5d agoAllarity Acquisition Corp., a newly formed SPAC affiliated with Allarity Therapeutics, publicly filed a Form S-1 registration statement with the SEC for a proposed initial public offering of its units.9d ago